16S profiling and metagenomics allowed a more in‐depth vision of our microbiota
1. Huge number of bacterial cells (3.8x1013)1, pathogens are subdominant2. Great diversity (estimated hundreds of species)3. Mostly un(hardly)culturable bacteria
A 10M genes catalogue!2
1Sender, R. PLoS Biol. 14, e1002533 (2016);2Li, J. Nat. Biotechnol. 32, 834–841 (2014). 4
16S profiling and metagenomics allowed a more in‐depth vision of our microbiota
4
Adapted from Sommer, F. & Bäckhed, F. Nat Rev Microbiol 11, 227‐238 (2013)
AllergyAlzheimerAtherosclerosisAutismBreast cancerCeliac diseaseCirrhosisColorectal cancerCrohn’sdiseaseEncephalopathyFrailty in seniorsHIVObesityParkinsonRheumatoid arthritisType 1 diabetesType 2 diabetesUlcerative colitis…You name it!
55
Is there any left condition unliked to the intestinal microbiota?
6
Antibiotics: barrier effect concentrations of resistant bacteria
Excretion of resistant bacteriaCross-transmissionSpread in environment
Carriage of resistantbacteriaSource of infectionGene transfer
AllergyAlzheimerAtherosclerosisAutismBreast cancerCeliac diseaseCirrhosisColorectal cancerCrohn’sdiseaseEncephalopathyFrailty in seniorsHIVObesityParkinsonRheumatoid arthritisType 1 diabetesType 2 diabetesUlcerative colitis…Resistance to antibiotics!
Adapted from Sommer, F. & Bäckhed, F. Nat Rev Microbiol 11, 227-238 (2013); Carlet, J. Antimicrob Resist Infect Control 1, 39 (2012).
The intestinal microbiota is the « epicentre of antibiotic resistance »
8Pamer, E. G. Science 352, 535–538 (2016).
The intestinal microbiota opposes to the settlement and overgrowth of exgenous bacteria: introduction to the barrier effect or colonization resistance
9
A consortium of 4 anaerobic bacteria collaborate to eradicate VRE from the gut in mice
1.Caballero, S. Cell Host & Microbe 21, 592–602.e4 (2017).
CBBP: C. bolteae, B. producta, B. sartorii and P. distasonis
Leo, S. et al. In preparation.
RNA extracted from feces cDNA synthesis and sequencing (Illumina) 16S and 23S analysis, multiple statistical analyses
1010
Some bacteria could be associated with a faster intestinal clearance of ESBL‐E. coli (but not with the acquisition)?
11Leo, S. et al. In preparation.
Some bacteria could be associated with a faster intestinal clearance of ESBL‐E. coli (but not with the acquisition)?
13
Have concentrations of resistant bacteria clinical consequences?
Bacterial translocation1
Urinary-tract infection2
Cross-transmission3
Long-term carriage4
Very low risk High risk
1Berg, R.D. et al. Infect Immun 33, 854-861 (1981); 2Ruppé, E. et al. Antimicrob. Agents Chemother. 2013, 57(9):4512; 3Donskey, C.J., et al. N Engl J Med 343, 1925-1932 (2000); 4Ruppé, E. et al. Clin Infect Dis. 61, 593–600 (2015).
Connelly S. J Appl Microbiol. 2017 Feb 28;
P1A beta‐lactamase from Bacillus subtilis and its derivative P3A manufactured in E. coli (Asp276Asn): Ribaxamase
17
Pre-treatment (D-4)
CRO+Ribaxamase (D4)
CRO (D4)
17
Inactivation of the antibiotic in the colonusing engineered beta‐lactamases
18de Gunzburg, J. et al. bioRxiv 169813 (2017).
Inactivation of the antibiotic in the colonusing engineered active charcoal
19de Gunzburg, J. et al. bioRxiv 169813 (2017).
Inactivation of the antibiotic in the colonusing engineered active charcoal
201Ubeda, C. et al. Infect. Immun. 81, 965–973 (2013); 2Millan, B. et al. Clin. Infect. Dis. (2016). doi:10.1093/cid/ciw185
Num
ber o
f ant
ibio
tic re
sist
ance
gene
s pe
r ind
ivid
ual
Mice1 Human2
Fecal material transplantation restores the barrier effect
7 health donors
Treatment (EtOH induced sporulation)
Encapsulation and storage at ‐80°C
SER‐109
21Khanna, S. et al. J Infect Dis. 214, 173–181 (2016). 21
Moving towards specific bacterial consortia
Khanna, S. et al. J Infect Dis. 214, 173–181 (2016).
The diversity of Enterobacteriaceae decreases (C), and Escherichia coli is restored as the prominent Enterobacteriaceae member.
2222
Already in motion (almost)
Wrap upInterplay betweenpathogens, ATB, resistance and commensals is far from beingunderstood
Several, complementarymethods are beingdeveloped: phages, colonicinactivation, FMT…
Let’s not forget to be cautious with the findings of metagenomic studies!
Yet new ideas to combat multidrug‐resistance emerge from a betterunderstanding of this interplay
Especially, preserving/restoring thebarrier effect in order to prevent theovergrowth of resistant bacteria
Indeed, lowering theconcentrations of resistantbacteria could have variousbenefits
23